Can VOYXACT move beyond proteinuria? Otsuka’s two-year VISIONARY data may decide its FDA future
Otsuka will unveil two-year VISIONARY eGFR data for VOYXACT, a pivotal test of kidney preservation and its path to full FDA approval.
Pharma & Biotech